FDA Clearance Tracker · P880086-S174
AFFINITY/INTEGRITY/VICTORY FAMILY OF PACEMAKERS
Last checked: Nov 20, 2026Latest source record: Jul 15, 2009 (this decision)Source: openFDAMethods & limitations
Decided
Jul 15, 2009
Approved
Time to decision
174 days
Received Jan 22, 2009. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P880086-S174
- Device name
- AFFINITY/INTEGRITY/VICTORY FAMILY OF PACEMAKERS
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Sylmar, CA
- Received
- Jan 22, 2009
- Decided
- Jul 15, 2009
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P880086
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ACCENT / ACCENT RF IMPLANTABLE PULSE GENERATORS AND ANTHEM / ANTHEM RF CRT-PS. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ACCENT / ACCENT RF IMPLANTABLE PULSE GENERATORS AND ANTHEM / ANTHEM RF CRT-PS. THE DEVICE IS INDICATED FOR: 1) MAINTAINING SYNCHRONY OF THE LEFT AND RIGHT VENTRICLES IN PATIENTS WHO HAVE UNDERGONEAN AV NODAL ABLATION FOR CHRONIC ATRIAL FIBRILLATION AND HAVE NYHA CLASS II OR III HEART FAILURE. 2) THE REDUCTION OF THE SYMPTOMS OF MODERATE TO SEVERE HEART FAILURE (NYHA CLASS IIIOR IV) IN THOSE PATIENTS WHO REMAIN SYMPTOMATIC DESPITE STABLE, OPTIMAL MEDICAL THERAPY, AND HAVE A LEFT VENTRICULAR EJECTION FRACTION <=35% AND A PROLONGED QRSDURATION. IMPLANTATION OF ACCENT, ACCENT RF, ANTHEM AND ANTHEM RF DEVICES IS INDICATED IN ONE OR MORE OF THE FOLLOWING PERMANENT CONDITIONS:A) SYNCOPEB) PRESYNCOPEC) FATIGUED) DISORIENTATION DUE TO ARRHYTHMIA/ BRADYCARDIAE) OR COMBINATION OF THOSE SYMPTOMS.RATE-MODULATED PACING IS INDICATED FOR PATIENTS WITH CHRONOTROPIC INCOMPETENCE, AND FOR THOSE WHO WOULD BENEFIT FROM INCREASED STIMULATION RATES CONCURRENT WITH PHYSICAL ACTIVITY.DUAL-CHAMBER PACING (ACCENT MODEL PM2110, ACCENT RF MODEL PM2210, ANTHEM AND ANTHEM RF DEVICES ONLY) IS INDICATED FOR THOSE PATIENTS EXHIBITING:A) SICK SINUS SYNDROMEB) CHRONIC, SYMPTOMATIC SECOND- AND THIRD-DEGREE AV BLOCKC) RECURRENT ADAMS-STOKES SYNDROMED) SYMPTOMATIC BILATERAL BUNDLE BRANCH BLOCK WHEN TACHYARRHYTHMIA AND OTHER CAUSESHAVE BEEN RULED OUT.ATRIAL PACING IS INDICATED FOR PATIENTS WITH SINUS NODE DYSFUNCTION AND NORMAL AV ANDINTRAVENTRICULAR CONDUCTION SYSTEMS.VENTRICULAR PACING IS INDICATED FOR PATIENTS WITH SIGNIFICANT BRADYCARDIA AND:A) NORMAL SINUS RHYTHM WITH ONLY RARE EPISODES OF A-V BLOCK OR SINUS ARRESTB) CHRONIC ATRIAL FIBRILLATIONC) SEVERE PHYSICAL DISABILITY....(SEE APPROVAL ORDER FOR ADDITIONAL APPROVAL INFORMATION)
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.